Endeavor BioMed

Endeavor BioMedicines is a clinical-stage biotechnology company focused on developing transformational medicines for life-threatening diseases, with a primary emphasis on fibrotic lung diseases and oncology. The company's lead candidate, taladegib (ENV-101), is a small-molecule inhibitor of the Hedgehog signaling pathway that targets the root cause of fibrosis by eliminating myofibroblasts. Clinical data from Phase 2a trials have demonstrated taladegib's potential to not only slow disease progression but also improve lung function and reverse fibrosis in patients with idiopathic pulmonary fibrosis (IPF). Additionally, Endeavor is advancing ENV-501, a next-generation HER3-targeted antibody-drug conjugate (ADC) licensed from Hummingbird Bioscience, for the treatment of HER3-positive solid tumors. Headquartered in San Diego, the company is supported by a syndicate of top-tier life science investors and led by an experienced management team with a track record of successful drug development.